Combination is key for us not only in developing products that target multiple aspects of the disease process and are suitable for use in combination with established standard therapies, but also for:
Combining innovative thinking with intelligent research and technical excellence ─ our Oncology franchise has brought together a dedicated group of individuals who can look beyond conventional horizons to explore further possibilities. They have the experience and motivation we need to identify potential therapeutic targets and develop novel cancer treatment strategies.
Combining insights, experience and skills ─ We are committed to working in partnership with oncology experts, healthcare providers and patients. We strive to meet the needs of patients for better medicines, and to improve access to these medicines by collaborative teamwork and sharing of skills. Moreover, this strategy combines the efficacy of radiotherapy, surgery and medical treatments to create a multidisciplinary approach for the benefit of cancer patients everywhere.
1Globocan 2008 http://globocan.iarc
The information contained in these pages is intended for general reference only. It may refer to pharmaceutical products, therapeutics or indications not yet registered or approved in a given country. This information should not be used to diagnose, treat, cure or prevent any disease without the advice of a qualified medical professional, and does not replace medical advice or a medical examination.
US Residents should consult EMD Serono, Inc. for information on products approved for sale in the United States of America.
For information on Erbitux, US Residents should consult ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company